Our results also observed the decrease of VEGF-A in the ischaemic region and TMZ administration significantly reversed the reduced VEGF-A level, which provides experimental evidence for the clinical application of TMZ in the treatment of ischaemic PAD. The gene discussed is VEGFA; the disease is peripheral arterial disease.